PCM
AVDL

Pentwater Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Pentwater Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,684,000
Closed -$36.3M – 94
2025
Q4 		$36.3M Buy
+1,684,000
New +$32.7M 0.19% 45

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Pentwater Capital Management's AVDL Position: Q1 2026 in Review

Pentwater Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,684,000 shares — an estimated $36.3M sold.

Pentwater Capital Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $36.3M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Pentwater Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Pentwater Capital Management sold 1,684,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $36.3M.
  • Pentwater Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Pentwater Capital Management's Avadel Pharmaceuticals position peaked at $36.3M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Pentwater Capital Management's 13F filing for Q1 2026, filed 15 May 2026.